Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer

Video

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Right now, there is not a clear-cut option for immunotherapy in the treatment of bladder cancer. It is currently up to treating physicians’ preference.

Every other day there are new data, says Black, and the community is just going to have to wait until the dust settles for a definitive answer.

Related Videos
Erin Crane, MD, MPH
Ibrahim Aldoss, MD
Minoo Battiwalla, MD
Arlene O. Siefker-Radtke, MD
Heinz-Josef Lenz, MD, FACP
Robert Wang, MD, of Fox Chase Cancer Center
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Changchun Deng, MD, PhD, associate professor, hematology/oncology, University Hospitals Seidman Cancer Center; member, Immune Oncology Program, Case Comprehensive Cancer Center
Jaime R. Merchán, MD